Biogen (BIIB) PT Raised to $320 at Barclays
Barclays raised its price target on Biogen (NASDAQ: BIIB) to $320.00 (from $295.00) while maintaining a Equalweight rating.
Analyst Geoff Meacham believes good Q2 results from Tuesday should provide downside support for the equity in Wednesday's trading session should the BAN2401 presentation not meet what he calls Street expectations. The analyst raises his estimates and thus his target price.